Spyre CFO sells 7,500 shares after option exercise

Spyre Therapeutics (SYRE) Chief Financial Officer Scott L. Burrows exercised stock options and sold shares in a pre-planned transaction.

Rhea-AI Filing Summary

Spyre Therapeutics (SYRE) Chief Financial Officer Scott L. Burrows exercised stock options and sold shares in a pre-planned transaction. On June 1, 2026, he exercised options to acquire 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in three open-market trades at weighted-average prices around the low $70s, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly holds 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments in 2026 and 2027, and continues to hold a large stock option covering hundreds of thousands of additional shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($424K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Burrows Scott L

Role Chief Financial Officer

Sold 7,500 shs ($533K)

Approx. gross sale proceeds $533K

Approx. exercise cost $109K

Approx. pre-tax spread $424K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$14.50	$109K
Sale	Common Stock	1,801	$69.75	$126K
Sale	Common Stock	2,599	$70.77	$184K
Sale	Common Stock	3,100	$72.06	$223K

Holdings After Transaction: Stock Option (Right to Buy) — 374,857 contracts (Direct); Common Stock — 97,994 shares (Direct)

Footnotes (6)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
6. F6. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Shares sold: 7,500 shares Sale prices: $69.75, $70.77, $72.06 per share Options exercised: 7,500 shares at $14.50/share +4 more

7 metrics

Shares sold 7,500 shares Common stock sold in three open-market trades on June 1, 2026

Sale prices $69.75, $70.77, $72.06 per share Weighted-average prices for three sale blocks of common stock

Options exercised 7,500 shares at $14.50/share Stock option exercise converting into common shares on June 1, 2026

Post-transaction holdings 105,494 shares Common stock directly held after transactions, including RSUs

Restricted stock units 67,476 RSUs Vesting in two equal installments on September 1, 2026 and 2027

Options remaining 374,857 options Stock options following the 7,500-share exercise; expire September 1, 2033

Total option grant size 404,857 shares Original option size adjusted for 1-for-25 reverse stock split

Key Terms

Rule 10b5-1 trading plan, restricted stock units ("RSUs"), weighted average price, reverse stock split, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units ("RSUs") financial

"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

reverse stock split financial

"This option represents a right to purchase 404,857 shares ... which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

stock option (Right to Buy) financial

"Stock Option (Right to Buy) ... This option represents a right to purchase 404,857 shares of the Issuer's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Spyre Therapeutics (SYRE) CFO Scott Burrows report?

Scott Burrows reported exercising options for 7,500 Spyre Therapeutics shares at $14.50 each and selling 7,500 common shares in three open-market trades at prices around $69.75 to $72.06, all executed on June 1, 2026.

Were Scott Burrows’ SYRE share sales made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the sales were pre-arranged rather than timed discretionarily in response to short-term market movements or news.

How many Spyre Therapeutics (SYRE) shares does the CFO hold after these transactions?

Following the transactions, Scott Burrows directly holds 105,494 shares of Spyre Therapeutics common stock. This total includes 67,476 restricted stock units that are scheduled to vest in two equal installments in 2026 and 2027, subject to continued employment.

What stock options does the SYRE CFO still have after exercising 7,500 shares?

The Form 4 shows an option position representing rights to purchase 404,857 Spyre Therapeutics common shares, with 374,857 options remaining after the 7,500-share exercise. The option was adjusted for a prior 1-for-25 reverse stock split and expires on September 1, 2033.

At what prices did the SYRE CFO sell his Spyre Therapeutics shares?

The reported sales used weighted-average prices, with individual trades occurring in ranges: $69.37–$70.36, $70.38–$71.34, and $71.54–$72.14 per share. Reported averages for the three listed sale blocks were $69.75, $70.77, and $72.06 per share, respectively.

What are the vesting terms for the SYRE CFO’s restricted stock units?

The filing notes 67,476 restricted stock units for the CFO. Each RSU represents one Spyre Therapeutics share upon vesting. These units vest in two equal installments on September 1, 2026 and September 1, 2027, contingent on his continued employment with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 09:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Scott L

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		M(1)		7,500	A	$14.5	105,494	D
Common Stock	06/01/2026		S(1)		1,801	D	$69.75(2)	103,693	D
Common Stock	06/01/2026		S(1)		2,599	D	$70.77(3)	101,094	D
Common Stock	06/01/2026		S(1)		3,100	D	$72.06(4)	97,994(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.5	06/01/2026		M(1)			7,500	(6)	09/01/2033	Common Stock	7,500	$0	374,857	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

6. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)